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Summary.-A random trial in which cyclophosphamide, nandrolone decanoate
and the two drugs in combination were used in the treatment of advanced breast
carcinoma is described. The results suggest that it is preferable to use cyclo-
phosphamide on its own.
WATSON and Turner (1959) have
suggested that a combination of thiotepa
and testosterone is superior to the agents
used singly. The object of this study
has been to assess whether combination
of a proven alkylating agent with an
androgenic steroid is more effective than
each agent used singly in patients with
advanced carcinoma of the breast and
within 5 years of the menopause. Pro-
visional results have been reported (Cole,
1970). Because thiotepa proved to be
rather toxic, cyclophosphamide was se-
lected for this trial. In an earlier series
of 79 patients with breast cancer who
received cyclophosphamide a response
rate of 30% (24/79) was recorded, as seen
in Table I.
TABLE I.-Comparison of Results ofTreat-
ment using Daily Oral and Weekly
Intravenous Cyclophosphamide
Num- Respond- Epila- Vomit-
ber ers tion ing
Daily oral cyclo.
phosphamide
Weeklv intra-
venous cyclo-
phosphamide
Totals
These patien
those within 5
Patients treated
up to 200 mg of cyclophosphamide daily,
whereas those treated intravenously were
given a single weekly injection of the
order of 800 mg, using a scalp tourniquet
in an attempt to prevent epilation.
As the oral route appeared to be as
effective as the intravenous route, and
as it was associated with a lower incidence
of vomiting, it was adopted for this
trial.
Nandrolone decanoate was also select-
ed for this test series because the use
of an injection avoids uncertainty about
sublingual absorption and the injections
of this compound need be no more
frequent than once every 3 weeks. There
is also less risk of jaundice than there is
with testosterone (Sherlock, 1968).
PATIENTS AND METHODS
Selection of patients.-Patients accepted
for inclusion in the trial were those with
histologically proven disease, with evidence
of dissemination or post-irradiation recur-
50 13 24 9 rence not amenable to further surgery or
radiotherapy. All patients had to be within
29 11 10 17 5 years of the menopause-either natural or
induced by ovarian irradiation. No other
79 24 34 26 cytotoxic or hormone therapy was permitted
from the original referral to entry into the ItS were not confined to trial. On entry to the trial patients were
years of the menopause. randomly allocated to one of the 3 groups
by the oral route received according to date ofbirth.TREATMENT OF ADVANCED CARCINOMA OF THE BREAST
Treatment schedules.-Group C, whose
date of birth fell between the 1st and 10th
of the month, received cyclophosphamide
alone in a dose of 50 mg thrice daily by
mouth, the dose being modified at later
visits according to the response and side-
effects (especially marrow depression).
Group N, whose date of birth fell between
the 11th and 20th of the month, received
nandrolone decanoate 50 mg by intra-
muscular injection every 3 weeks.
Group C + N, whose date of birth fell
between the 21st and 31st of the month,
received both agents according to the same
schedules as Groups C and N.
Assessment of response.-Response to
treatment was assessed by change in visible,
palpable or radiologically demonstrated de-
posits of tumour. A positive response was
accepted if there was regression of more
than 50% sustained for 3 months or more.
RESULTS
Eighty-three patients were entered
into the trial but 5 are excluded for the
following reasons: Two in Group C + N
died soon after starting treatment (at 3
days and at 2 weeks because of advanced
disease); one in Group C + N and one
in Group N were given a hormone pre-
paration, prednisolone, before the trial
drugs could be started; and one in
Group C took the cyclophosphamide for
2-3 days, stopped it because she started
an antibiotic and did not recommence it.
The number of patients in each group,
and mean age at entry, are shown in
Table II.
TABLE II.-Mean Age at Entry
Group Number Age
C
N
C+N
Total
.30
26
22
46*8±6 *5
50 3±5*2
45 6±6 ±65
78
The 3 groups were studied for factors
which might influence response to treat-
ment but they seemed to be very similar.
The stages at presentation and the
proportions subjected to surgery or to
radiotherapy as the initial management
showed little difference between the
groups. Local recurrence was the com-
monest indication for treatment and
arose in 64 (86%) patients. The majority
of patients with local recurrent disease
had evidence of disease in other sites.
There was no difference in the distribution
of disease between groups, in particular
the incidence of metastases in bone and
liver.
Response
The number of patients in whom a
positive response was recorded is shown
in Table III.
TABLE III.-Number of Patients with
Positive Objective Response with Mean
Duration (Months)
C
N
C4
Group Number
30
26
-N 22
Totals 78
Number of
patients with
response
7
0
1
8
Mean
duration
(months)
6 *2
8
A positive response was recorded in
8 patients (10%), 7 of whom received
cyclophosphamide alone. No patient
who received nandrolone alone responded
and only one patient who received the
combination responded.
Eighteen additional patients showed
an improvement which fell short of the
criteria for a positive response and details
are given in Table IV.
A comparison was made between
patients in whom a response was noted
TABLE IV.-Number ofPatients with
Partial Response
C
Response but
under 50%
tumour
Group Number regression
30 6
26
22
78
4
8
18
N
C+N
Totals
Total,
including
responders
from
Table III
13
4
9
26
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and those who showed no improvement,
to assess whether any particular feature
could be identified that could indicate
the possibility of a favourable response
in future patients. The only positive
feature noted was the higher proportion
of patients with metastatic bone disease
in those who did not respond to the
therapeutic course.
Patients receiving cyclophosphamide
alone had the longest mean period of
survival (17.3 months), the survival period
for the other 2 groups being similar (10
months). The mean survival for those
patients with a positive response was 21
months compared with 11-7 months for
those who did not (P = 0.10).
Side-effects
Adverse reactions were recorded in
31 (42%) patients. In 29 patients these
were directly attributable to the drug
and in the remaining two were a possi-
bility. Details are given in Table V.
TABLE V.-Incidence ofAdverse
Reactions
Group
a N C+N Depression of white cell count
below 3000/mm3 9 0 7
Anaemia 1 0 0
Epilation 7 0 8
Vomiting 6 0 3
Haematuria 1 0 0
Tumour pain 0 2 0
Treatment stopped 11 2 9
The number and nature of side-
effects in those patients receiving cyclo-
phosphamide and in those who received
the combination were very similar. Five
patients in the former group and 3 in the
latter group were responding to treatment
which had to be discontinued in view of
depressed haemopoiesis.
DISCUSSION
Inthisstudy cyclophosphamide proved
to be the most effective agent, a positive
response occurring in 23% of patients.
Only one patient who received the com-
bination of cyclophosphamide and nan-
drolone decanoate responded, and no
response was noted in those receiving
nandrolone alone.
Since nandrolone as a single agent
is so ineffective in this menopausal
group, it is not surprising that, in com-
bination with cyclophosphamide, it adds
nothing to the results achieved with
cyclophosphamide alone. The unexpect-
ed finding in this trial is the relatively
poor result obtained from the combination
when compared with the use of cyclo-
phosphamide alone. A possible explana-
tion for this finding is that nandrolone
interferes with the activation of cyclo-
phosphamide. It now seems clear that
cyclophosphamide is activated in the
liver (Brock et al., 1971; Brock, 1967;
Foley, Friedman and Drolet, 1961) and
there is evidence that prednisolone in-
hibits the activation of cyclophosphamide
by rat liver (Hayakawa et al., 1969).
It is possible that nandrolone decanoate
shares this property with prednisolone.
However, the findings from this trial
do not entirely support this hypothesis
since if the cyclophosphamide is not
being so freely activated in the group
also receiving nandrolone, one would
expect a further lowering of the incidence
of adverse reactions, such as marrow
depression and epilation, but this was not
observed.
Conclusion
Cyclophosphamide is more effective
when used alone in these menopausal
patients with advanced breast cancer than
when combined with nandrolone deca-
noate.
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